Cancer

ProstACT-TARGET

A Single Arm Trial of External Beam Radiation Therapy (EBRT) in Combination with 177Lu-DOTA-TLX591 Theranostic in Patients with Biochemically Recurrent, Oligometastatic, Prostate Specific Membrane Antigen- Expressing Prostate Cancer

Trial overview

Topic

Prostate cancer

Eligibility criteria

Inclusion

  • Signed Informed Consent Form
  • Male, aged ≥ 18 years
  • Estimated life expectancy of at least 6 months
  • Eastern Cooperative Oncology Group (ECOG) score 0 - 2
  • Biopsy proven prostate adenocarcinoma with Gleason Score 7 or more at primary presentation
  • Previous Radical Prostatectomy (RP) with curative intent (+/- post-operative radiotherapy to prostate bed)
  • Biochemical relapse, as defined by EAU-ESTRO-SIOG Guidelines (serum PSA > 0.2 ng/mL, confirmed by repeat measurements)
  • PSMA-ligand avid pelvic nodal disease on PSMA-ligand PET/CT, with visualised disease confined to the pelvis with or without evidence of PSMA-avid disease in the prostate bed
  • At least one pelvic nodal lesion ≥ 5 mm in the greatest dimension. SUVmax > 9 in enlarged nodes; SUVmax > 3 in nodes 5 mm or less
  • Oligometastatic disease as defined by ≤ 5 metastatic lymph nodes
  • Metastatic lymph nodes not beyond the aortic bifurcation
  • Non-castrate levels of testosterone (> 20 ng/dL)
  • Chemotherapy naïve
  • Adequate renal function: Cr Cl ≥ 40 mL/min (determined by Cockcroft-Gault formula)
  • Adequate bone marrow function: Hb > 90 g/L; platelets > 100 x 109/L; neutrophils > 1.5 x 109/L
  • Adequate liver function: bilirubin < 1.5 x upper limit of normal (ULN); AST, ALT, ALP < 2 x ULN; albumin > 30 g/L
  • Willing and able to comply with all trial requirements, including all treatments and pre- and post-treatment assessments
  • Able to commence treatment within 28 days of enrolment

Exclusion Criteria:

  • Previous external beam radiotherapy to pelvis for other malignancies or medical conditions (except for post-operative prostate bed radiotherapy for prostate cancer)
  • Have received other investigational agents within 4 weeks of enrolement
  • Androgen deprivation therapy within 12 months of trial screening
  • Known androgen deficiency
  • Bone or visceral metastases
  • Lymph node metastases above the aortic bifurcation
  • Contraindications to pelvic irradiation as determined by Investigator (e.g., chronic inflammatory bowel disease)
  • At increased risk of haemorrhage, or recent history of a thrombotic event (e.g., Deep Vein Thrombosis [DVT]/Pulmonary Embolism [PE]) and/or are using long-term anti-coagulant or anti-platelet agents)
  • Known hypersensitivity to any isotope of lutetium (Lu) in any chemical form, or any isotope used in PSMA imaging
  • Contraindication to intravenous contrast
  • Evidence of urinary tract stricture, or significant urinary/faecal incontinence 
  • Presence of active infection at time of screening, or history of serious infection within the previous 4 weeks
  • History of any malignancy other than prostate cancer within 5 years of enrolment (excluding localised non-melanoma skin cancers)
  • Any uncontrolled significant medical, psychiatric, or surgical condition (e.g., active infection, unstable angina pectoris, cardiac arrhythmia, poorly controlled type 2 diabetes, uncontrolled congestive heart failure, pulmonary disease), or laboratory findings that, in the opinion of the Investigator, may jeopardise the participant's safety or that would limit compliance with the treatment and assessment requirements of the trial
  • Any cognitive impairment or other condition that may render the participant unable to adequately understand the requirements, nature, and possible consequences of the trial.
  • Intention to father children within a timeframe corresponding with the duration of the allocated treatment regime plus 12 weeks

Study details

This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer. TLX591 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radiosotope for the treatment of PSMA-expressing tumours.

Further information

Please click here for more information.

Location

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.